Avanza Fonder AB Increases Holdings in Amgen Inc. $AMGN

Avanza Fonder AB lifted its position in Amgen Inc. (NASDAQ:AMGN) by 12.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 64,357 shares of the medical research company’s stock after buying an additional 7,150 shares during the period. Avanza Fonder AB’s holdings in Amgen were worth $21,065,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of AMGN. Laurel Wealth Advisors LLC lifted its holdings in Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after acquiring an additional 6,676,575 shares during the period. Norges Bank bought a new stake in shares of Amgen during the 2nd quarter valued at about $1,663,726,000. Capital World Investors grew its stake in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares during the period. National Bank of Canada FI increased its position in shares of Amgen by 237.7% during the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares during the last quarter. Finally, Van ECK Associates Corp increased its position in shares of Amgen by 71.8% during the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock valued at $383,254,000 after purchasing an additional 567,400 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.6%

Amgen stock opened at $349.77 on Tuesday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market capitalization of $188.55 billion, a price-to-earnings ratio of 24.58, a P/E/G ratio of 3.45 and a beta of 0.45. The firm has a 50 day moving average of $360.77 and a 200 day moving average of $328.60. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s payout ratio is 70.84%.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of research reports. TD Cowen reissued a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Daiwa Securities Group upped their target price on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Cantor Fitzgerald increased their price target on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Truist Financial lifted their price target on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Finally, Freedom Capital downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $354.60.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.